Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. - Wikidata - awgldk - TriplyDB

Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

http://www.wikidata.org/entity/Q34214649

about

Use of rifaximin in gastrointestinal and liver diseases New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists Pregnane X receptor as a target for treatment of inflammatory bowel disorders FXR signaling in the enterohepatic system Sustained Isoprostane E2 Elevation, Inflammation and Fibrosis after Acute Ischaemia-Reperfusion Injury Are Reduced by Pregnane X Receptor Activation PXR variants: the impact on drug metabolism and therapeutic responses Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis Novel functions of PXR in cardiometabolic disease.Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice.Marine and semi-synthetic hydroxysteroids as new scaffolds for pregnane X receptor modulation Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer Current and emerging drugs for the treatment of inflammatory bowel disease.Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation Pregnane X receptor- and CYP3A4-humanized mouse models and their applications.Post-translational modification of pregnane x receptor.Intestinal pregnane X receptor links xenobiotic exposure and hypercholesterolemia.Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach Small-molecule modulators of PXR and CAR.Decreased Pregnane X Receptor Expression in Children with Active Crohn's Disease.Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial.Tanshinone IIA ameliorates dextran sulfate sodium-induced inflammatory bowel disease via the pregnane X receptor.Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice PXR antagonists and implication in drug metabolism.Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain.Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis.Targeting nuclear receptors with marine natural products.Challenges and opportunities of metabolomics.Xenobiotic receptor humanized mice and their utility.PXR cross-talks with internal and external signals in physiological and pathophysiological responses.Pregnane X receptor polymorphisms associated with human diseases.LC-MS-based metabolomics: an update.Rifaximin: beyond the traditional antibiotic activity.Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.Rifamycins, Alone and in Combination.Identification of three novel natural product compounds that activate PXR and CAR and inhibit inflammation Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole.

P2860

Q26740201-020FE6AA-378E-4C4A-B141-A0BD1B618D5E Q26748617-A44D4557-DCEE-4887-ABFC-9ECA6553A24B Q26998347-F945017F-B27C-4CFD-9DA0-E411E67A2A6F Q27014753-32D57589-3F17-4109-8250-D7C4E529564F Q27322581-3D948211-F29A-43AE-8936-E1E08114220F Q28080023-87509053-25D2-492B-B137-462B13311E02 Q28481350-6FBDC584-C419-421C-A796-F5264C3851F3 Q30251861-818F1E5B-82D2-4320-A5A2-31B0E190FDB1 Q33756030-3144A955-F7FC-4497-A051-DC37A4B10BF4 Q33808887-3F5FF0FE-8B9C-434A-94FD-DA97A763AE3B Q34573895-1D52031E-5F44-4866-8385-9A4F99DAA89D Q34883210-93570577-8977-4EAC-A103-51116A934171 Q34946639-FA31E1BA-5F8D-441A-8CC4-95B73C348300 Q35005644-17B46A97-2D76-4073-9060-F090942635AB Q35034168-729EEB43-DBF1-462E-AB9A-80C7A25DC01A Q35555694-6D2AF4FA-B3DB-4F29-B929-35BC65419636 Q35855737-EC492FBD-F42B-4A9B-9033-8B8793103332 Q35870133-53C96879-7CBC-4191-A0C2-720E8008CC1E Q35938150-BFC06691-26E6-43BE-B7D8-CA020B0E44B5 Q35969912-286CFA5B-EF6D-40EF-8EA7-3DED09F92687 Q36009729-A7BE784F-083D-459E-B8DA-C10F5AAAD83C Q36157264-1407E613-060C-4FD7-9C77-2F0CCC6679DB Q36365170-565F8CD5-988A-4CE0-9F0B-88553684C7EF Q36379917-9FE7B9AF-CAE4-47DF-BE69-CE8C8852E2F0 Q36640752-F5435934-62F3-4036-AA08-E81BE6D6077B Q36852609-9FEBAC14-1FBD-4EBF-8A7D-EFE278566297 Q36945155-B9BB706A-9E93-465A-A96D-855AB540F941 Q37053805-A6F69BF9-11A7-40A5-82B8-9B39657CE136 Q37566161-B2EEC454-CFD5-479C-B378-C89724A3856C Q37621100-8EA78B37-ECF3-4646-B8A4-A4D0F9365803 Q37950296-51A7F636-B04A-4BEB-81F4-088E38B32DA0 Q38061645-F766BEA8-8EAF-494E-9571-B19567A837FF Q38108791-AB25579F-D39D-45C2-930B-4C548E28B3AC Q38138603-16F9C91A-3595-41B9-8CAB-ADFECAED3BE1 Q38202881-A4E4FE26-3C62-4FB0-901A-63891CFC7ADB Q38237218-F4B3175B-BE83-42EB-B9B9-BF00988D8E1A Q38692607-90BDB782-E423-4714-8D0F-B153078B3C87 Q38857578-D5382E4A-CF1A-4AF5-9528-E76BBBA79243 Q39118521-AD7408F6-2090-4CD5-8C96-7819DF78E4CC Q39205301-5436D69A-3799-48B9-BA5B-1D129397153C

P2860

Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.

http://www.wikidata.org/entity/Q34214649

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Therapeutic role of rifaximin ...... regnane X receptor activation.

@ast

Therapeutic role of rifaximin ...... regnane X receptor activation.

@en

Therapeutic role of rifaximin ...... regnane X receptor activation.

@nl

type

label

Therapeutic role of rifaximin ...... regnane X receptor activation.

@ast

Therapeutic role of rifaximin ...... regnane X receptor activation.

@en

Therapeutic role of rifaximin ...... regnane X receptor activation.

@nl

prefLabel

Therapeutic role of rifaximin ...... regnane X receptor activation.

@ast

Therapeutic role of rifaximin ...... regnane X receptor activation.

@en

Therapeutic role of rifaximin ...... regnane X receptor activation.

@nl

P1433

Q34214649-35D458B4-620E-421B-978B-F6BB5B24779C

P1476

Q34214649-EA0E13B6-E016-4BF2-9C26-8FBA6E9F89A8

P2093

Q34214649-134A2037-2DA2-4020-B172-9A5D486994F7

Q34214649-487E61A1-48AC-4E48-A2B7-2EFE8172E5A4

Q34214649-7A0D98B0-0AFA-424F-98BB-44FF0DBD05F9

Q34214649-85088BBB-1B04-43C0-A7CD-EF5D90260FF4

Q34214649-A2116FBE-49FB-4A9F-B454-E716E28DF765

Q34214649-AECB0705-5B4C-434E-B895-E2AC2A3BE4D4

Q34214649-C46703BD-F714-4240-9A22-C4A677E63E17

Q34214649-ECC44368-A6AC-4B53-B622-F5AAE87A842B

P2860

Q34214649-2E5B7428-D493-4D73-A83D-A2C7988611DE

Q34214649-301A5DB3-EA1E-4523-A360-DE1491B80BA1

Q34214649-352A6586-4ED7-45BF-A8B8-CBDABBC11B4E

Q34214649-3AE0558A-5A6A-478F-877F-4F43C75D78E0

Q34214649-3FEE62F3-7D6F-4F3C-AAB6-25ECC4458F89

Q34214649-4F583D19-839B-40FD-8892-0E3689F475C9

Q34214649-540EEC93-77E7-4CC8-8B91-A7F01381317F

Q34214649-60FD4AEE-336D-4B73-849E-6DDC92D3EC94

Q34214649-6358A124-AAF6-4BDE-AC00-809601F2D7CE

Q34214649-6B432CA9-3CCE-41EC-82A5-DB41011017D5

P304

Q34214649-AB734F21-0B0A-4377-BC5E-CA914380D1CD

P31

Q34214649-298DD0A0-0ED0-4918-87E2-F078C5062B44

P356

Q34214649-7673A5EC-1FC3-4FED-8103-C7D61A721037

P407

Q34214649-4E56D0A4-AB30-4583-97BD-BD3211770497

P433

Q34214649-767445A0-D885-4D7B-B898-B0D3692778D5

P478

Q34214649-71DE9A07-47C4-4238-90CF-D966D4B19211

P577

Q34214649-0404C7D7-28C3-4AB2-8D6B-6783D8A7367E

P5875

Q34214649-A9459F7C-4C0F-4F5C-B626-176856E7E37F

P698

Q34214649-CBE9F8AA-42B9-410B-903D-FDA256064574

P921

Q34214649-33D6D26D-02FC-4892-B0B2-CFDE94DE6D64

Q34214649-AB2AD6E9-C047-4FDC-B3CD-3E8E830EEDA2

P932

Q34214649-9F013449-7929-4020-8F38-C6B6C3A428ED

P356

JPET.110.170225

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Therapeutic role of rifaximin ...... regnane X receptor activation.

@en

P2093

Frank J Gonzalez

http://www.w3.org/2001/XMLSchema#string

Jie Cheng

http://www.w3.org/2001/XMLSchema#string

Kristopher W Krausz

http://www.w3.org/2001/XMLSchema#string

Tatsuhiko Kodama

http://www.w3.org/2001/XMLSchema#string

Toshiya Tanaka

http://www.w3.org/2001/XMLSchema#string

Xiaochao Ma

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Pang

http://www.w3.org/2001/XMLSchema#string

Yatrik M Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction

The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution

Inflammatory bowel disease

A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway.

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation

Animal models of inflammatory bowel disease: an overview.

2004 drug approval highlights: FDA update.

Antimicrobials in the management of inflammatory bowel disease.

Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis

P304

32-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.110.170225

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

335

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45185237

http://www.w3.org/2001/XMLSchema#string

P698

20627999

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

2957776

http://www.w3.org/2001/XMLSchema#string